Drug Patents owned by Acacia
1. List of Barhemsys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
| US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
| US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
| US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(10 years from now) | |
| US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 2024-02-27
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS
BARHEMSYS family patents
11
United States
4
United Kingdom
4
European Union
3
Israel
3
Croatia
3
Denmark
3
Spain
3
Cyprus
3
Portugal
3
Poland
3
Japan
3
Slovenia
3
Mexico
3
RS
2
Australia
2
EA
2
Korea, Republic of
2
Canada
2
San Marino
2
Brazil
2
China
1
New Zealand
1
Norway
1
Hong Kong
1
Hungary
1
Lithuania
2. List of Byfavo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US9737547 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
| US10052334 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
| US9827251 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
| US10195210 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
| US10342800 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
| US10722522 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
| US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 6, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 2024-10-06
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
BYFAVO family patents
16
United States
8
European Union
5
China
4
Korea, Republic of
4
Hong Kong
3
Japan
3
United Kingdom
2
Australia
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Slovenia
1
EA
1
Croatia
1
Canada
1
Austria
1
Russia
1
Germany
1
Mexico
1
RS
1
Brazil
1
Hungary
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic